RYR2 and catecholaminergic polymorphic ventricular tachycardia: These defects align with targets of current treatment of CPVT, which includes the administration of β blockers, flecainide to reduce RyR2 opening, L-type Ca2+ channel blockers such as verapamil and use of an implantable cardioverter defibrillator (ICD) [3,4,8,68].